CryoPort, Inc. (CYRX) Earnings Call Analysis

NASDAQ · Industrials · Integrated Freight & Logistics

25/25

Growth 5 Margin 5 Expansion 5 Platform 5 Financial 5

latest quarter score

Earnings Reports

25
CryoPort (CYRX) Q2 2026: Life Science Services Hit 15% Growth, Margin Expansion Signals Sustained Profitability Path
August 07, 2026
20
CryoPort (CYRX) Q1 2026: Commercial Cell & Gene Therapy Revenue Jumps 26% as Pipeline Matures
May 05, 2026
21
Cryoport (CYRX) Q4 2025: Commercial Cell & Gene Therapy Revenue Surges 29%, Anchoring Long-Term Growth
March 04, 2026
20
Cryoport (CYRX) Q3 2025: Cell & Gene Therapy Revenue Climbs 36% as Commercial Pipeline Expands
November 05, 2025
21
Cryoport (CYRX) Q2 2025: Service Revenue Climbs 21% as DHL Partnership Recasts Global Reach
August 06, 2025
23
Cryoport (CYRX) Q1 2025: Life Sciences Services Now 56% of Revenue as DHL Deal Reshapes Strategic Focus
July 04, 2025
CryoPort (CYRX) Q4 2024: Commercial Cell & Gene Therapy Revenue Surges 37%, Gross Margin Expands 520 Basis Points
March 04, 2025

Browse all companies